Introduction: Our purpose of this study is to evaluate the effect and safety of macitentan in the treatment of pulmonary hypertension (PH).
Methods: We retrieved the safety and efficacy of macitentan treatment for PH using PubMed, the Cochrane Library, EMBASE databases and clinicaltrials.gov. The Cochrane Risk of Bias Tool was used for literature screening and quality assessment. Data analysis was conducted using RevMan 5.4.1 and Stata/SE 15.1 software. Results are presented as standardization mean differences (SMDs) and odds ratio (OR).
Results: Meta-analysis of seven randomized controlled trial (RCT) studies and four non-RCT studies with 2769 patients was included, involving 723 in the macitentan group and 599 in the placebo group. The results of the study showed that macitentan had effectively decreased pulmonary vascular resistance (PVR) (SMD = -0.53, 95% CI: -0.77--0.29, p < 0.05), cardiac index (CI) (SMD = 0.60, 95% CI: 0.37-0.83, p < 0.05) and N-terminal pro-brain natriuretic peptide (NT-proBNP) (SMD = -0.22, 95% CI: -0.40--0.03, p < 0.05). Furthermore, macitentan also significantly reduced PVR (SMD = -0.58, 95% CI: -0.80--0.35, p < 0.05), 6-min walk distance (6WMD) (SMD = 0.33, 95% CI: 0.15-0.50, p < 0.05), CI (SMD = 0.48, 95% CI: 0.28-0.69, p < 0.05), mean pulmonary arterial pressure (mPAP) (SMD = -0.43, 95% CI: -0.64--0.23, p < 0.05) and NT-proBNP (SMD = -0.55, 95% CI: -1.07--0.03, p < 0.05) between baseline and follow-up. The adverse reactions to macitentan were mild, with headache, anaemia and bronchitis. Other efficacy and safety outcomes did not reach statistical differences.
Conclusion: Macitentan therapy for PH is effective and safe. The effectiveness on PVR, mPAP, mean right atrial pressure (mRAP), mortality and other indicators still needs to be further confirmed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632077 | PMC |
| http://dx.doi.org/10.1111/crj.13621 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Macitentan is a dual endothelin receptor antagonist (ERA) approved for treating pulmonary arterial hypertension (PAH). SOPRANO evaluated the efficacy and safety of macitentan versus placebo in pulmonary hypertension (PH) patients after left ventricular assist device (LVAD) implantation. SOPRANO was a phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group study.
View Article and Find Full Text PDFArticle Synopsis
- The OPUS/OrPHeUS studies focused on patients with pulmonary arterial hypertension (PAH) related to congenital heart disease (CHD), collecting data on their real-world clinical practices and treatment outcomes while starting on macitentan.
- A total of 272 patients (6.1% of the population) were identified with CHD-PAH, where most were in moderate functional health categories, and many began macitentan as part of combination therapy; a high percentage experienced adverse events, but survival rates were relatively positive over one and two years.
- The findings indicate that macitentan is commonly used in CHD-PAH patients, with its safety profile matching existing knowledge,
Long-Term Safety and Efficacy of Macitentan in Inoperable Chronic Thromboembolic Pulmonary Hypertension: Results from MERIT and its Open-Label Extension.
Pulm Ther
November 2024
German Center for Lung Research (DZL), Giessen, Germany and University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany.
Introduction: Evidence for use of pulmonary arterial hypertension targeted-therapies in patients with chronic thromboembolic pulmonary hypertension (CTEPH) is limited. In MERIT-1, the endothelin receptor antagonist macitentan improved hemodynamic and functional parameters versus placebo in patients with inoperable CTEPH over a 24-week double-blind (DB) period. Its open-label (OL) extension study (MERIT-2) provides long-term safety/efficacy data.
View Article and Find Full Text PDFAn in-depth evaluation of the efficacy and safety of various treatment modalities for chronic thromboembolic pulmonary hypertension: A systematic review and network meta-analysis.
Am Heart J Plus
October 2024
Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Article Synopsis
- Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition that significantly impacts prognosis, and this study aimed to evaluate the effectiveness and safety of various treatments available for it.
- The research reviewed 14 randomized controlled trials involving 1,047 patients, focusing on key outcomes like exercise capacity (6-minute walk distance) and pulmonary pressures.
- Findings indicated that treatments such as balloon pulmonary angioplasty (BPA) and pulmonary artery dilatation with nitroglycerin (PADN) were the most effective, improving exercise capacity and pulmonary function while reducing side effects and mortality rates.
Prediction of Severe Baseline Asymptomatic Carotid Stenosis and Subsequent Risk of Stroke and Cardiovascular Disease.
Stroke
November 2024
Department of Vascular Surgery (G.J.B.), University Medical Center Utrecht, Utrecht University, the Netherlands.
Article Synopsis
- The study evaluated the PACAS risk model's ability to identify patients at high risk for severe asymptomatic carotid artery stenosis (ACAS) and predict future strokes and cardiovascular disease (CVD) risk.
- It involved 26,384 patients aged 45-80, finding that 6.3% had severe ACAS at baseline and that higher PACAS scores correlated with increased incidences of stroke and CVD over roughly 70,000 patient-years of follow-up.
- The PACAS model was confirmed to effectively discriminate and calibrate risk levels, indicating that patients with higher scores had a significantly higher prevalence of severe ACAS and related events during the follow-up period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!